For patients with vulvar cancer, the best discrimination was obtained for a cut-off value of post-therapeutic numbers of CD133+ CTCs ≥ 14/ml (50% sensitivity and 100% specificity; Supplementary Figure S4A), numbers of CD49f+ CD133+ CTCs ≥ 5/ml (88.89% sensitivity and 86.36% specificity; Supplementary Figure S44B) and numbers of PD-L1+ CD49f+ CD133+ CTCs ≥ 5/ml (100% sensitivity and 100% specificity; Supplementary Figure S4C). This evidence concerns the gene ITGA6 and vulva cancer.